

Global Neuromyelitis Optica Spectrum Disorder Market Forecast To Reach \$3.52 Billion By 2029 With 8.4% Annual Growth

*The Business Research Company's
Neuromyelitis Optica Spectrum Disorder
Global Market Report 2025 – Market Size,
Trends, And Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, May 14, 2025
[/EINPresswire.com/](https://EINPresswire.com/) -- The

neuromyelitis optica spectrum disorder

market has shown robust growth in recent years and is poised to continue its upward trajectory. It is projected to grow from \$2.35 billion in 2024 to \$2.55 billion in 2025, reflecting a compound annual growth rate CAGR of 8.7%. This encouraging growth can be attributed to the increasing prevalence of NMOSD, rising awareness and early diagnosis, developing therapeutic options and

FDA approvals, expanding research and development activities, and increasing clinical trials for innovative treatment modalities.



The Business Research
Company's Latest Report
Explores Market Driver,
Trends, Regional Insights -
Market Sizing & Forecasts
Through 2034"

*The Business Research
Company*

Is the Neuromyelitis Optica Spectrum Disorder Market Set to Witness Substantial Growth?

Over the next few years, the NMOSD market is expected to experience even stronger growth, projected to reach \$3.52 billion in 2029, with a CAGR of 8.4%. This surge is largely driven by increasing awareness and early diagnosis, rising healthcare expenditures, burgeoning investments in

research and development, growing prevalence of autoimmune diseases, increasing clinical trials for NMOSD therapies, and a burgeoning demand for personalized medicine.

Major trends forecast for this period include advancements in precision medicine, collaboration and partnership initiatives, technological innovations, integration of AI and big data in research, and a significant shift towards home-based treatments.

Get Your Free Sample Market Report:

The Business
Research Company

The Business Research Company



What Drives The Neuromyelitis Optica Spectrum Disorder Market Growth?

Noteworthy catalysts propelling the market's growth include the rising prevalence of multiple sclerosis. As a chronic autoimmune disease affecting the central nervous system, multiple sclerosis causes inflammation, nerve damage, and neurological symptoms.

The progressive prevalence of this condition is attributed to improving diagnostic techniques, environmental influences, and genetic predisposition. Advancements in medical imaging, such as MRI, have facilitated earlier and more precise diagnoses, leading to a rise in identified cases. This, in turn, has heightened awareness of neurological autoimmune diseases, enhancing diagnostic methodologies, and increasing recognition of NMOSD.

For instance, in May 2024, the Multiple Sclerosis Trust, a UK-based national charity, reported around 7,100 new multiple sclerosis cases annually in the UK and approximately 135 new diagnoses each week. This rising prevalence is driving the growth of the NMOSD market.

Who Are The Key Players In The Neuromyelitis Optica Spectrum Disorder Market?

In this competitive landscape, major companies operating in the NMOSD market include F. Hoffmann-La Roche Ltd., AstraZeneca, Merck KGaA, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd., the Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc., and Oregon Health & Science University among others.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/neuromyelitis-optica-spectrum-disorder-global-market-report>

What Are The Emerging Trends In The Neuromyelitis Optica Spectrum Disorder Market?

A key trend in the market is the development of innovative products such as long-acting complement inhibitors, aimed at enhancing treatment efficacy and improving patient outcomes. These treatments suppress the complement system for extended periods, preventing inflammation and nerve damage in NMOSD, reducing relapses, and supporting long-term disease control.

For example, in March 2024, Alexion Pharmaceuticals and AstraZeneca received approval for ULTOMIRIS ravulizumab-cwvz for the treatment of adults with anti-aquaporin-4 AQP4 antibody-positive NMOSD. This approval established Ultomiris as the first and only long-acting C5 complement inhibitor available for NMOSD treatment.

How Is The Neuromyelitis Optica Spectrum Disorder Market Segmented?

The NMOSD market is segmented by Type, Diagnosis, Treatment Type, Distribution Channel, and End-User. Subsegments include NMOSD with or without Aquaporin-4 AQP4 Antibodies and various types of NMOSD associated with other autoimmune disorders, providing a

comprehensive overview of the market dynamics.

What Is The Regional Analysis Of Neuromyelitis Optica Spectrum Disorder Market?

Geographically, North America accounted for the largest share of the NMOSD market in 2024. However, Asia-Pacific is forecasted to be the fastest-growing region. Other regions covered in the report include Western Europe, Eastern Europe, North America, South America, the Middle East and Africa, offering detailed insights into each area's market dynamics.

Browse Through More Similar Reports By The Business Research Company:

Autism Spectrum Disorders Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/autism-spectrum-disorders-treatment-global-market-report>

Neurotechnology Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/neurotechnology-global-market-report>

Neuroscience Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report>

About The Business Research Company:

The Business Research Company boasts a repository of over 15000+ reports spanning 27 industries and 60+ geographies. It prides itself on comprehensive, data-rich research and insights. Armed with 1.5 million datasets, in-depth secondary research, and unique insights from industry leaders, it provides valuable data that helps you to stay ahead in the game.

Get in touch:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us: info@tbrc.info

Stay connected:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/812494793>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.